Drugs / ZG-801
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04955678 | Aug 2021 → Dec 2022 | — | Zeria Pharmaceutical | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-09-24 | Zeria Pharmaceutical | Regulatory 高カリウム血症治療薬(ビルタサ)製造販売承認取得のお知らせ zeria.co.jp ↗ |
| 2024-09-24 | CSL Behring | Regulatory Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia csl.com ↗
CSL Vifor today announced that Japan's Ministry of Health and Labor Welfare (MHLW) has granted its partner, Zeria Pharmaceutical Co., Ltd. (Zeria), marketing authorization approval for Veltassa ® for the treatment of adult patients with hyperkalemia, a condition characterized by high levels of potassium in the blood. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-09-24 | Zeria Pharmaceutical | 高カリウム血症治療薬(ビルタサ)製造販売承認取得のお知らせ zeria.co.jp ↗ |
| 2024-09-24 | CSL Behring | Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia csl.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZG-801 | “ZG-801 is powder for suspension.” NCT04955678 ↗ |